# Lamivudine for Chronic Hepatitis B

> **NCT00001457** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 60 (—)

## Conditions studied

- Chronic Hepatitis B
- Chronic Hepatitis D
- Glomerulonephritis
- Polyarteritis Nodosa

## Interventions

- **DRUG:** Lamivudine

## Key facts

- **NCT ID:** NCT00001457
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-09
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 60 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001457, "Lamivudine for Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00001457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*